AbbVie completed the acquisition of Cerevel Therapeutics for $8.7bn.

AbbVie, a global biopharmaceutical company, completed the acquisition of Cerevel Therapeutics, a biopharmaceutical company focused on developing new therapies, for $8.7bn. "AbbVie's acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the next decade and beyond. Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living with neurological and psychiatric conditions. We are excited to welcome the talented Cerevel team to AbbVie," Robert A. Michael, AbbVie CEO.